nonprofit logo

Parker Institute For Cancer Immunotherapy

Learn about this cause: Is it Legit? Do I like the mission? What is the CEO's salary?

EIN: 473355381 ✦ San francisco, CA ✦ Designated as a 501(c)(3)

Overview

What is Parker Institute For Cancer Immunotherapy?

The Parker Institute for Cancer Immunotherapy (PICI) is a leading nonprofit organization based in San Francisco, California, with a workforce of 92 individuals. Its primary objective is to catalyze the progress of cancer immunotherapy research, collaboration, and discovery, ultimately translating these advances into cures and treatments for patients. PICI conducts its own research and clinical trials while offering its consortium of renowned hospitals and academic research centers shared research resources, such as scientific equipment, consumables, bioinformatics analysis, and a specimen biobank. The institute also funds and supports cancer immunotherapy research within its network. The mission of PICI is to accelerate the development of groundbreaking immune therapies, transforming all cancers into manageable diseases.


Official website here: www.parkerici.org

Is Parker Institute For Cancer Immunotherapy legitimate?

Parker Institute For Cancer Immunotherapy is a legitimate nonprofit organization registered as a 501(c)(3) entity. Parker Institute For Cancer Immunotherapy submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.

Here are some key statistics you may want to consider:

Executive Compensation: $2,237,353
Professional Fundraising Fees: $0
Other Salaries and Wages: $15,406,447

For more financial information, click here


Official website here: www.parkerici.org

What is the mission statement of Parker Institute For Cancer Immunotherapy?

The Parker Institute for Cancer Immunotherapy (PICI) is dedicated to expediting the development of groundbreaking immune therapies to transform cancer into manageable diseases. Through its own research and clinical trials, as well as collaborations with leading hospitals and academic research centers, PICI fosters advances in cancer immunotherapy. The institute provides its consortium with shared research resources like scientific equipment, consumables, bioinformatics analysis, and a specimen biobank. Moreover, PICI funds and supports cancer immunotherapy research within its network.


Official website here: www.parkerici.org

Who is the CEO of Parker Institute For Cancer Immunotherapy?

Ute Dugan is the Principal Officer of Parker Institute For Cancer Immunotherapy.


Official website here: www.parkerici.org

What is the revenue of Parker Institute For Cancer Immunotherapy?

Parker Institute For Cancer Immunotherapy's revenue in 2022 was $32,769,137.


Official website here: www.parkerici.org

Who are the executives of Parker Institute For Cancer Immunotherapy and what are their salaries?

The average compensation at Parker Institute For Cancer Immunotherapy during 2022 was $191,780. There are 92 employees and 19 volunteers at Parker Institute For Cancer Immunotherapy.

Here are 26 key members and their salaries:

    John Connolly Phd (Chief Scientific Officer)
  • Compensation: $854,600
  • Related: $0
  • Other: $34,231

    • Ute Dugan Md (Chief Medical Officer)
  • Compensation: $751,934
  • Related: $0
  • Other: $43,380

    • Tarak Mody (Chief Business Officer)
  • Compensation: $586,752
  • Related: $0
  • Other: $43,381

    • Justin Fairchild (Vp Clinical Dev. Thru 9/30/22)
  • Compensation: $535,136
  • Related: $0
  • Other: $33,360

    • Shane Corcoran (Senior Vp, Strat. Ops. & Comms)
  • Compensation: $521,356
  • Related: $0
  • Other: $42,581

    • Lisa Butterfield (Vp Res. & Dev. Thru 7/31/22)
  • Compensation: $525,443
  • Related: $0
  • Other: $29,610

    • Sara Coblin (Sr Vp Finance & Admin.)
  • Compensation: $522,112
  • Related: $0
  • Other: $31,096

    • Lacey Padron (Vp Informatics)
  • Compensation: $400,026
  • Related: $0
  • Other: $38,873

    • Sean N Parker (Chair Of The Board & Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Michael Polansky (Executive Vp & Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Tom Van Loben Sels (Treasurer & Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Jeffrey A Bluestone Phd (Vice Chair & Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Tony Coles Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Eric Esrailian Md Mph (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Scott Gottlieb Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Ben Horowitz (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Jeff Huber (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Bob Hugin (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Reed Jobs (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Joel Marcus (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Bob Nelsen (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Bruce Parker Phd (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Bob Pittman (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Ramy Ibrahim Md (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Margo Georgiadis (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0

    • Susan Dawson (Secretary)
  • Compensation: $0
  • Related: $0
  • Other: $0


  • Official website here: www.parkerici.org

    Where can I find the form 990 for Parker Institute For Cancer Immunotherapy?

    The Parker Institute For Cancer Immunotherapy’s most recent form 990 was submitted in 2022 and can be accessed here


    Official website here: www.parkerici.org

    Learn more at the official website: www.parkerici.org

    Mission Statement of Parker Institute For Cancer Immunotherapy

    The Parker Institute for Cancer Immunotherapy (PICI) is a pioneering organization dedicated to revolutionizing cancer treatment through the development of groundbreaking immune therapies. With a mission to transform all cancers into manageable diseases, PICI fosters advances in research, collaboration, and discovery within the realm of cancer immunotherapy.

    To achieve this ambitious goal, the Parker Institute engages in its own research and clinical trials while supplying its consortium of prestigious hospitals and academic research centers with vital shared resources. These resources include scientific equipment, consumables, bioinformatics analysis, and a specimen biobank, collectively contributing to the acceleration of immunotherapy research and the eventual translation of these advancements into curative treatments for patients.

    Furthermore, PICI extends its support beyond its consortium by funding and assisting cancer immunotherapy research in various spheres, ultimately driving innovation in the field and bringing hope to those battling cancer.

    Impact

    This information is meant to be a general summary of Parker Institute For Cancer Immunotherapy. Please take the time to review official sources before making any decisions based upon the content provided here.




    Thursday, August 15, 2024

    The Parker Institute for Cancer Immunotherapy has a significant impact on advancing cancer immunotherapy research, collaboration, and discovery. By conducting its own research and clinical trials and providing shared research resources to its consortium of hospitals and academic research centers, the institute plays a crucial role in translating scientific advances into cures and treatments for cancer patients. Through funding and supporting cancer immunotherapy research within its consortium, the institute is at the forefront of accelerating the development of breakthrough immune therapies to potentially turn all cancers into curable diseases.





    Financials

    This financial information is from Propublica.

    Revenue
    Expenses
    Efficiency

    Other financial information:

    This information is from the most recently submitted tax form from this organization, which was in 2022.

  • Investment Income: $15,719,892
  • Program Service Revenue: $13,501,237
  • Gross Receipts: $40,446,762

    • Assets and Liabilities:
  • Total Assets: $307,154,607
  • Total Liabilities: $57,635,216
  • Net Assets: $249,519,391
  • Programs

    Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.

    RESEARCH STUDY SPONSORSHIP

    Revenue

    $10,876,237

    LICENSE FEES

    Revenue

    $2,625,000

    Organization Details

    Founding Year

    2015

    Principal Officer

    Ute Dugan

    Main Address

    1 LETTERMAN DRIVE D3500, SAN FRANCISCO, CA, 94129

    NTEE Category

    Code: E12 - Health

    If you are a representative of Parker Institute For Cancer Immunotherapy and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.